AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Giacometti, A. R.
Right arrow Articles by Davis, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Giacometti, A. R.
Right arrow Articles by Davis, P. C.

American Journal of Neuroradiology, Vol 14, Issue 1 123-127, Copyright © 1993 by American Society of Neuroradiology


ARTICLES

Comparison of full- and half-dose gadolinium-DTPA: MR imaging of the normal sella

AR Giacometti, GJ Joseph, JE Peterson and PC Davis
Emory University School of Medicine, Department of Radiology, Atlanta, GA 30322.

PURPOSE: This study compares sellar intensities in 17 patients without sellar pathology using half (0.05 mmol/kg, nine patients) and full-dose (0.1 mmol/kg, eight patients) gadopentetate dimeglumine (Gd-DTPA). METHODS: Sellar MR studies of eight patients who received full and nine patients who received half-dose Gd-DTPA were compared, retrospectively. Sequences included pre-, immediate, and delayed postcontrast T1- weighted coronal images (1.5 T). Intensity measurements were obtained by two observers using a uniform region of interest. RESULTS: Comparison of normalized intensities revealed no significant difference between intensities obtained from immediate half- and full-dose techniques for any of the tissues examined (Student's t test, P < .90). Delayed scans likewise demonstrated no significant intensity differences between full- and half-dose studies. CONCLUSION: Our findings suggest that a 50% reduction in dosage of Gd-DTPA for sellar MR at 1.5 T results in no significant diminution in intensity of enhancement of the pituitary gland or adjacent tissues.